S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Price, News & Analysis

$3.00
-0.18 (-5.66%)
(As of 03/28/2024 ET)
Today's Range
$2.90
$3.11
50-Day Range
$2.55
$3.49
52-Week Range
$1.11
$3.53
Volume
648,205 shs
Average Volume
354,429 shs
Market Capitalization
$193.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

GlycoMimetics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
233.3% Upside
$10.00 Price Target
Short Interest
Healthy
2.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.65mentions of GlycoMimetics in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.60) to ($0.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.42 out of 5 stars

Medical Sector

124th out of 938 stocks

Pharmaceutical Preparations Industry

47th out of 423 stocks

GLYC stock logo

About GlycoMimetics Stock (NASDAQ:GLYC)

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GLYC Stock Price History

GLYC Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
GlycoMimetics' (GLYC) "Buy" Rating Reaffirmed at HC Wainwright
Q4 2023 GlycoMimetics Inc Earnings Call
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
GlycoMimetics: Q4 Earnings Snapshot
GLYC Apr 2024 2.500 call
GLYC Apr 2024 2.500 put
GlycoMimetics Inc hosts conference call for investors
GLYC Apr 2024 5.000 call
Palatin Technologies Inc.
GlycoMimetics Inc GLYC
GlycoMimetics, Inc. (GKO.F)
See More Headlines
Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2023
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GLYC
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+233.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-46,690,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
$0.82 per share

Miscellaneous

Free Float
59,294,000
Market Cap
$193.35 million
Optionable
Optionable
Beta
2.19
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Harout Semerjian (Age 54)
    CEO, President & Director
    Comp: $1.1M
  • Ms. Rachel K. King (Age 65)
    Co-Founder & Director
    Comp: $226.43k
  • Mr. Brian M. Hahn (Age 50)
    Senior VP & CFO
    Comp: $748.27k
  • Ms. Stephanie R. Irish CPA (Age 53)
    Vice President of Accounting
  • Mr. Christian B. Dinneen-Long
    General Counsel & Company Secretary
  • Mr. Bruce Johnson (Age 56)
    Senior VP & Chief Commercial Officer
  • Dr. Edwin Rock M.D. (Age 63)
    Ph.D., Senior VP & Chief Medical Officer
  • Mr. Chinmaya Rath (Age 47)
    Senior VP & Chief Business Officer
  • Mr. Shantha Tyavanagimatt Ph.D.
    Senior Vice President of Technical Operations

GLYC Stock Analysis - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings
or view top-rated stocks.

What is GlycoMimetics' stock price target for 2024?

2 brokers have issued 12 month target prices for GlycoMimetics' stock. Their GLYC share price targets range from $8.00 to $12.00. On average, they anticipate the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 233.3% from the stock's current price.
View analysts price targets for GLYC
or view top-rated stocks among Wall Street analysts.

How have GLYC shares performed in 2024?

GlycoMimetics' stock was trading at $2.36 at the beginning of the year. Since then, GLYC stock has increased by 27.1% and is now trading at $3.00.
View the best growth stocks for 2024 here
.

When is GlycoMimetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our GLYC earnings forecast
.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) announced its quarterly earnings results on Friday, November, 3rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.14). During the same period last year, the firm posted ($0.16) EPS.

What other stocks do shareholders of GlycoMimetics own?
Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Goldman Sachs Group Inc. (1.43%), Goldman Sachs Group Inc. (1.43%), GSA Capital Partners LLP (0.31%), Bridgeway Capital Management LLC (0.31%), Northern Trust Corp (0.17%) and MJP Associates Inc. ADV (0.16%). Insiders that own company stock include Brian M Hahn, Bruce S Johnson, Daniel M Junius, Edwin Rock, John L Magnani, Patricia S Andrews, Public Equities LP Invus and Scott D Sandell.
View institutional ownership trends
.

How do I buy shares of GlycoMimetics?

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLYC) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners